Background Early identification of patients who will benefit from immune checkpoint
inhibitors (ICIs) has recently become a hot issue in cancer immunotherapy. Peripheral …

Abstract Introduction: Circulating tumour DNA (ctDNA) is an emerging biomarker in
melanoma. We performed a systematic review and meta-analysis to explore its clinical utility …

Currently, checkpoint inhibitor‐based immunotherapy has emerged as prevailing treatment
modality for diverse cancers. However, immunotherapy as a first‐line therapy has not …

Background Quantification of circulating tumor DNA (ctDNA) levels is a reliable prognostic
tool in several malignancies. Dynamic changes in ctDNA levels in response to treatment …

Background Detection of circulating tumour DNA (ctDNA) in biological fluids is a minimally
invasive alternative to tissue biopsy for therapy monitoring. Cytokines are released in the …

Cutaneous melanoma is an immunogenic highly heterogenic tumor characterized by poor
outcomes when it is diagnosed late. Therefore, immunotherapy in combination with other …

Simple Summary The analysis of circulating tumor DNA (ctDNA) concentrations in blood
plasma and the radiomic analysis of tumor images (ie, quantification of textural features on …

BACKGROUND Gut microbiome (GM) composition and diversity have recently been studied
as a biomarker of response to immune checkpoint blockade therapy (ICB) and of ICB-related …

Background The use of immunotherapy targeting the programmed cell death protein-1 (PD-
1) and its ligand (PD-L1) has provided new hope for patients with non-small cell lung cancer …

Simple Summary Metastatic melanoma treatment has greatly changed in the last decade
due to the introduction of target therapies and immune checkpoint inhibitors. The …